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Abstract
Background—Epidemiologic studies have reported that frequent consumption of quercetin-rich
foods is inversely associated with lung cancer incidence. A quercetin-rich diet might modulate
microRNA (miR) expression; however, this mechanism has not been fully examined.
Methods—miR expression data were measured by a custom-made array in formalin-fixed
paraffin-embedded tissue samples from 264 lung cancer cases (144 adenocarcinomas and 120
squamous cell carcinomas). Intake of quercetin-rich foods was derived from a food-frequency
questionnaire. In individual-miR-based analyses, we compared the expression of miRs (n=198)
between lung cancer cases consuming high-versus-low quercetin-rich food intake using
multivariate ANOVA tests. In family-miR-based analyses, we used Functional Class Scoring
(FCS) to assess differential effect on biologically functional miRs families. We accounted for
multiple testing using 10,000 global permutations (significance at p-valueglobal <0.10). All
multivariate analyses were conducted separately by histology and by smoking status (former and
current smokers).
Results—Family-based analyses showed that a quercetin-rich diet differentiated miR expression
profiles of the tumor suppressor let-7 family among adenocarcinomas (p-valueFCS<0.001). Other
significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and
miR-17 (p-valuesFCS<0.05). In individual-based analyses, we found that among former and
current smokers with adenocarcinoma, 33 miRs were observed to be differentiated between
highest-and-lowest quercetin-rich food consumers (23 expected by chance; p-valueglobal = 0.047).
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Conclusions—We observed differential expression of key biologically functional miRNAs
between high-versus-low consumers of quercetin-rich foods in adenocarcinoma cases.
Impact—Our findings provide preliminary evidence on the mechanism underlying quercetin-
related lung carcinogenesis.
Introduction
Quercetin is a polyphenol ubiquitously present in certain fruits (e.g., apples and grapes) and
vegetables (e.g., onions, kale, broccoli, lettuce, and tomatoes) and has been found to possess
anticarcinogenic properties (1). We (2) and others (3–5) previously observed that a
quercetin-rich diet was associated with lower risk of lung cancer in epidemiologic studies.
Quercetin and quercetin-rich foods may prevent carcinogenesis via several mechanisms,
including free radical scavenging, pro-apoptotic and anti-proliferation pathway mediation,
modification of anti-inflammatory responses, and activation of detoxifying Phase II enzymes
(6–9).
New findings suggested that polyphenol compounds like quercetin are more likely to
interact with cellular signaling cascades that regulate transcription factors (10). More
specifically, in vivo and in vitro studies showed that they modulate a wide range of miR
expressions and may consequently influence carcinogenesis (11–13). MiRs are short, non-
coding, single-stranded RNAs involved in gene expression of multiple target mRNAs (14).
Mis-regulated miRs have been implicated in many cancers where they act to promote over-
expression of oncogenes and under-expression of tumor suppressor genes (14, 15). For
example, the let-7 class of miRs function as tumor suppressors by repressing cell
proliferation and regulating both RAS and c-myc oncogenes (16). In lung cancer, we
previously showed that the let-7 family is differentially expressed by histology and is
associated with survival in the Environment And Genetics in Lung Cancer Etiology
(EAGLE) study (17).
Polyphenolic compounds, including quercetin, have been shown in experimental studies to
alter expression of several cancer-related miRs, including the cancer-associated let-7 family
(18–23). Quercetin metabolites were observed to modulate miR-155 in murine macrophages
(18) and miR-146a in colon cancer cells (21). Another polyphenol, Epigallocatechin, has
been shown to up-regulate miR-16 in human hepatocellular cells (23). Additionally,
differential expression of the let-7 family and other miRs was observed in human
hepatocellular cancer cells exposed to Ellagitannin (22).
The emerging evidence from in vitro and in vivo investigations provides biological rationale
to examine the influence of quercetin on miR expression in lung carcinogenesis in the
present epidemiologic study. As a follow-up study to our observation that a quercetin-rich
diet was inversely associated with lung cancer in EAGLE participants (2), we investigated
the influence of quercetin-rich food consumption on miR expression signatures in lung
tissues of EAGLE lung cancer patients. Given the importance of let-7 in lung carcinogenesis
(24, 25) and their association with polyphenols (20), we specifically focused on several
members of the let-7 family as a priori candidates for quercetin modification. To our
knowledge, this is the first mechanistic investigation of this nature using human tissues in
relation to dietary quercetin-rich food consumption.
Materials and Methods
Study population
The present study is based on 144 adenocarcinoma (AD) and 120 squamous cell carcinoma
(SQ) subjects from the EAGLE case-control study. The EAGLE study design has been
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previously described (26). Briefly, EAGLE is a population-based case-control study of lung
cancer conducted in the Lombardy region of Italy between 2002 and 2005. Primary,
incident, lung cancer cases (N=2100) were recruited from 13 hospitals that examined ~80%
of all cases within the catchment area, which included 5 cities (Milan, Monza, Brescia,
Pavia, and Varese), surrounding towns, and villages. The majority of cases (95%) were
confirmed by pathology reports and the remaining cases by imaging and documentation of
clinical history. Histologic type was recorded for all cases.
miR expression data
We previously described the miR expression data from EAGLE (17). Briefly, the miR
expression data were derived from formalin-fixed paraffin-embedded (FFPE) tissue samples
in 144 lung adenocarcinoma and 120 squamous cell carcinoma cases from EAGLE. The 264
individuals included in the current study were a subgroup with both dietary quercetin
information and miR expression data. These individuals did not differ markedly in relevant
characteristics (e.g. age, sex, body mass index, smoking, and alcohol consumption,
Supplemental Table S1) from EAGLE lung cancer cases that were excluded due to lack of
data on quercetin and/or miR expression data.
The miRs were analyzed using a custom-made, two-channel oligo-array using one EBV cell
line as the reference sample. The array included a total of 713 human, mammalian, and viral
mature antisense miRs plus 2 internal controls with 7 serial dilutions. Intensities for
duplicate spots of each miR were averaged. Individual miRs with low overall signal
intensity (<100) in both channels and/or low signal/noise ratio were excluded. A spot size
smaller than 25 pixels and miRs with >50% missing data were additionally filtered out.
Global median normalization was utilized as the most robust method with median-
normalization calculated by subtracting out the median log-ratio for each array. Of the 440
human miRs, a total of 198 miRs were retained in the final analysis and are reported in
Supplemental Table S2. We validated five miRs (let-7g, let-7f, miR-26a, miR-638, and
miR-107) by qRT-PCR using Taqman miR assays (Applied Biosystems) in 49 EAGLE
samples normalized to Endogenous Control RNU6B that had sufficient tumor miR
expression remaining after array analysis (17).
Epidemiologic and Quercetin-rich food data
At baseline, epidemiologic data were collected using both a computer-assisted personal
interview and a self-administered questionnaire to address potential risk factors associated
with lung cancer, including comprehensive data on smoking exposure and dietary intake
specific to this Italian population (26). Dietary intake in the previous year was obtained from
a self-administered 58 item food frequency questionnaire (FFQ) where frequency of
consumption was designated using 11 possible response categories that ranged from ‘never’
to ‘2 or more times a day’. Quercetin-rich food items (apples, grapes, onions, artichoke/
fennel/celery, beans/chick peas, plum, turnips, peppers, strawberries, tomatoes, and
broccoli) in the FFQ were identified based on data published in the United States
Department of Agriculture on food-specific quercetin content (>0.50mg/100g) (27). We
created a summary measure of quercetin-rich foods by adding the seasonal frequency of
intake reported for the individual food item (2).
Statistical analysis
Quercetin-rich food intake was divided into sex-specific tertiles based on the distribution of
the controls from the EAGLE study (2). We further defined highest and lowest consumers of
quercetin-rich foods to be those in the third and first tertile, respectively. We previously
showed that miR levels differed by histology in this population (17) and miR expression
might be associated with smoking status (28). To address potential residual confounding by
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smoking and differential effect by histology, all our analyses were performed for smoking-
specific (former and current smokers) and lung cancer subtype (adenocarcinoma and
squamous cell carcinoma). Although we examined the influence of quercetin-rich food
intake on miR expression in never smokers, the results were unstable and not reported due to
too few individuals (n=28).
Individual-miR-based analyses—We first compared the expression levels of 198 miRs
between highest (T3) and lowest (T1) quercetin-rich food consumers using multivariate
ANOVA tests. Models were adjusted for age (continuous), sex, body mass index
(continuous), pack-years of smoking (continuous), consumption of non-quercetin-rich fruits
and vegetables(continuous), red/processed meats (continuous), and lifetime alcohol
consumption (continuous). In the larger EAGLE study, frequency of quercetin-rich intake
was correlated with frequency of non-quercetin rich fruits and vegetables (r=0.64) and
consumption of red/processed meat (r=0.07). Selection of other covariates was based on
factors that have been associated with either miR expression or lung cancer risk. Individual
food items comprised within the individual food groups are described in Supplemental Table
S3.
To further address the issue of multiple comparisons we calculated a global p-value (pglobal).
For this calculation, we randomly permuted the highest and lowest classes of quercetin
intake 10,000× where the number of significant miRs from ANOVA testing was recorded
(nP). The global p-value was then defined as one plus the number of times in which np was
at least as large as the number of original significant miRs divided by 10,000.
There is a lack of data on quercetin-associated effects on miR expression in human tissues in
the current literature, particularly at habitual consumable level. In order to minimize false
negative findings at the initial analyses, we considered a permuted pglobal < 0.10 to be
statistically significant.
Family-miR-based analyses—We grouped each miR into known biological functional
families using MiRBase release 17.0. We assembled miRs into families based on unique
‘seed sequence’ (nucleotides 2–7 at the 5′ end) and identified 21 miR families
(Supplemental Table S4). A piori, we restricted our family-miR-based analyses to 9 miR
families with at least one miR identified at a p-value < 0.05. We used Functional Class
Scoring (FCS) to compare the expression profile of each miR family between high-versus-
low consumers of a quercetin-rich diet.
FCS computes p-values by assigning all miRs within a particular group (or family) an
aggregate raw score (the arithmetic mean of the negative natural logarithm of each p-value
obtained from miR analyses) (29). This raw score was then compared to the score of
randomly derived groups of the same size through q repeated samplings (q=1,000). Each
score was ordered in ascending order to build an empirically derived score distribution. The
FCS p-value was determined as the fraction of randomly sampled groups having a higher
score than the group score of interest. For these analyses, we defined statistical significance
at a p-valueFCS <0.05. We further evaluated the statistical significance using the more
conservative Bonferroni p-value (0.05/9= 0.006).
Permutations were performed in the statistical package R. All other analyses were performed
using SAS, version 9.2.
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Results
In the present study, lung cancer cases had a mean age at diagnosis of 65 years. Table 1
presents the distribution of selected characteristics by tertiles of quercetin intake, separately
for adenocarcinoma and squamous cell carcinoma. Among ever smokers, highest (T3)
consumers of quercetin-rich foods smoked less and were more likely to be AD cases
compared with low consumers. Former smokers on average consumed more servings of
quercetin-rich foods per day than current smokers (1.65±0.88 vs. 1.29±0.79). Compared
with AD cases, SQ cases tended to be males, smoked more, and consumed more alcohol and
meat across tertiles of quercetin intake. Never smokers (n=29) were all AD except for one
individual.
Individual- miR-based expression
We identified 16 miRs that were differentially expressed for AD (4 miRs) and SQ (12 miRs)
cases (p-values < 0.05) between high-versus-low consumers of quercetin-rich foods (Table
2). Likewise, 19 miRs were differentially expressed for former (12 miRs) and current (7
miRs) smokers (see Supplemental Table, S5).
Table 3 presents analyses examining the influence of quercetin-rich diet on miR expression
within histologic subtypes for former and current smokers separately. Considering the four
sub-groups, we identified overall 48 unique miRs that were differentially expressed between
highest-vs-lowest quercetin-rich consumers (p-value < 0.05, Table 3).
Among former and current smokers with AD, 33 miRs were observed to be differentiated
between highest and lowest quercetin-rich consumers (23 expected by chance; p-valueglobal
= 0.047, Table 3). For SQ cases, we identified 15 miRs (p-valueglobal = 0.15, Table 3).
Quercetin-mediated miR expression profiles appeared to be more prevalent among former
smokers with AD compared with current smokers. In this group, we identified 25 miRs with
a p-value < 0.05 (22 expected by chance; p-valueglobal = 0.076; see Supplemental Figure 1
for heat map). The largest fold-change was observed for miR-26b, a proapoptotic miR (fold-
change = 2.00; p-value = 0.020). Notably, among the identified significant miRs, all of the
let-7 family members (let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, and miR-98)
were associated with a quercetin-rich diet. Moreover, the majority of let-7 family members
were up-regulated with increasing frequency of quercetin intake (Figure 1).
In comparison to AD cases, far fewer miRs were identified at a p-value <0.05 among SQ
cases. None of the SQ subgroups was statistically significant (p-valuesglobal > 0.10).
Family- miR-based expression
Table 4 presents the results examining the association of quercetin-rich foods with families
of miRs in smoking-specific analyses for AD and SQ cases. A quercetin-rich diet appears to
significantly differentiate miR expressions in former smokers with AD. Among this group,
our data showed that the let-7 family was strongly differentiated by a quercetin-rich diet (p-
valueFCS < 0.001, Table 4) followed by miR-146 (p-valueFCS = 0.002), miR-26 (p-valueFCS
= 0.010), and miR-17 (p-valueFCS = 0.031). Both the let 7 and the miR-146 families
remained significant after Bonferroni correction for multiple comparisons
(pbonferonni=0.05/9 = 0.006). We observed no significant difference in miR expression for
SQ cases and current smokers regardless of histology.
Figure 1 graphically depicts the directionality of quercetin-associated miR expression of
let-7, miR-146, miR-26, and miR-17 families with a quercetin-rich diet for formers smokers
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with AD. In general, members of the let-7 family, miR-26 as well as miR-146b were up-
regulated. In contrast, the expression of miR-146a was downregulated.
Discussion
We previously observed that higher consumption of quercetin-rich foods was associated
with lower risk of lung cancer in a large population-based case-control study in Italy (2).
The present study tests the hypothesis that a quercetin-rich diet modulates the expression of
miRs in human lung tissues. In individual-miR-based analyses, we identified significant
quercetin-mediated miR expression signatures for 48 unique miRs. These identified miRs
have been shown to decrease tumor metastasis and invasion (miR-146a/b, -503, and -194),
decrease cell proliferation (miR-125a, -155, let-7 family, -302c, -195, -26a, -503, and -215),
increase apoptosis (miR-125a, -605, -26b, let-7g, -34a, -491, and -16), and target tumor
suppressors (let-7 family, miR-125a, -183, -146a, -98, -19b, -106a, and -381). In family-
miR-based analyses, we found that the large majority of members of the let 7 family was
strongly up-regulated among former smokers with AD who consumed a higher intake of
quercetin compared with low consumers (p-valueFCS < 0.001). We also observed similar
family-based results for miR-146, miR-26, and miR-17 families (p-valueFCS < 0.05) in this
group.
Due to its association with lung cancer (25) and possibly with polyphenols (20), we
specifically focused on the let-7 class of miRs in relation to a quercetin-rich diet. In addition
to being the most statistically significant result based on FCS in the family-based analyses,
the let-7 family remained significant after Bonferroni correction at p-value < 0.006.
Members of the let-7 family are known to function as tumor suppressors in lung carcinoma
by repressing NSCLC cell proliferation (16, 30) and by negatively regulating the RAS
oncogene (31). Among the let-7 miRs in the present study, let-7a, a known suppressor of k-
RAS and c-Myc oncogenes (32), exhibited the largest fold change (fold-change = 1.46). Our
data suggest a possible mechanism of quercetin-related tumor protection through the
increased expression of these key tumor suppressors.
We also observed differential quercetin-mediated expression of the miR-17 family
(miR-20a, -20b, -106a, -106b, -17, and -93) in former smokers with AD. MiR-17 family
belongs to the oncogenic miR-17-92 cluster (33). Investigators have shown that the
miR-17-92 cluster is frequently overexpressed in lung cancer (25, 34). Expression of
miR-17 is associated with poorer prognosis and cellular proliferation (35) while miR-106b
targets p21 and subsequently promotes cell cycle progression (36). Additionally,
suppression of miR-20a induces apoptosis in lung cancer (37). In our study, the majority of
the miRs (67%) in miR-17 family were downregulated in frequent consumers of quercetin-
rich food among former smokers with AD.
Quercetin-rich food consumption also significantly differentiated miR-146 and miR-26
families in our study. Neither of these miR families has been extensively studied with
respect to lung carcinogenesis; however, both families have been associated with tumor
development. In lung alveolar epithelial cells, miR-146 was observed to negatively regulate
pro-inflammatory chemokines (38). Additionally, miR-146a is one of two known miRs
(miR-146a and -155) involved in inflammatory signaling pathways and has been observed to
be up-regulated by quercetin in experimental study (21). We corroborated this up-regulation
of miR-146a among higher consumers of quercetin in the present study. One study showed
that miR-155, was downregulated with quercetin in murine cells (18). In lung carcinoma,
miR-155 has often been seen to be up-regulated and to have prognostic impact (39).
However, it has also been suggested to function as a tumor suppressor by repressing cell
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proliferation (40). In the present study, however, miR-155 was not significant in the
individual-miR-based analyses by histology and smoking status.
Both miR-26a and miR-26b exhibited the greatest fold change in our individual miR-based
analyses (miR-26a, FC=1.78) and (miR-26b, FC=2.00). Our data suggest that a quercetin-
rich diet increases the expression of the miR-26 family, which has been shown to suppress
cell proliferation in nasopharyngeal carcinoma through G1 phase arrest and repression of c-
Myc (41) as well as to induce apoptosis in breast cancer cells (42). Proapoptotic
characteristics of miR-26 make this particular group of miRs an important candidate for
study in future research investigating quercetin-mediated miR-targets.
We previously identified a miR expression profile that strongly differentiated
adenocarcinoma from squamous cell carcinoma with prognostic implications in EAGLE
(17). Results from this present study showed consumption of quercetin-rich foods is
associated with differential miR expression by histology. In general, our data suggest that
quercetin-rich foods influenced miR expression in tumor tissues of former smokers with
AD, but not for SQ and current smokers. The modest fold-change effect of dietary quercetin
on miR expression might only be detectable in a milieu that is less saturated by smoking
exposure, as in former smokers and in AD which is less associated with smoking than SQ
(43). Furthermore, AD cases included in the present study on average smoked less intensely
than SQ cases. The anti-carcinogenic capabilities associated with dietary quercetin may be
weakened in SQ cases by competing tobacco-related carcinogens.
To our knowledge, the present study is the only investigation examining the association
between dietary quercetin, at a habitual consumable level, and miR expression in lung
tissues. In addition to having both dietary information and miR expression data, this study
included several variables that allowed tight control for potential confounders. This richness
of epidemiologic data coupled with epigenetic data from human tissues permitted an
integrative approach—making it possible to explore underlying mechanisms that may
explain the protective effect of quercetin and lung cancer risk seen in observational studies.
Despite its uniqueness, the study had a limited sample size, which reduces statistical
precision, and explored a limited number of human miRs. Although the EAGLE
questionnaire assessed food consumption a year prior to the study, we cannot exclude that
the lung cancer diagnosis had influenced the patients’ responses. However, this potential
recall bias should not have differentially affected the adenocarcinoma or squamous cell
carcinoma cases, and could not explain the different association with quercetin by histology
type. Secondly, the northern Italian population comprised of the EAGLE study consumed
very high intake of meat products (44) and in contrast substantially lower intake of fruits and
vegetables; therefore the FFQ captured a limited variety of food sources of quercetin as
reflective of the consumption in this population. While our exposure measure of quercetin-
rich diet is likely subject to measurement errors, the errors however would be nondifferential
errors and would not alter our findings and conclusion. Moreover, we did not measured
quercetin content directly; thus, we cannot rule out the contribution of other flavonoids or
nutrients that are found in those foods.
In conclusion, we observed that a quercetin-rich diet is associated with differential
expression of key miRs in lung tissue within smoking specific histology groups. Notably,
expression of miRs in the let-7 family, a known tumor suppressor, was strongly associated
with frequent quercetin-rich food intake in the present study. Our findings provide
suggestive insights into a possible mechanism to explain the inverse association between
quercetin-rich food consumption and lung cancer risk observed in epidemiological studies.
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Confirmation in a larger prospective study with both dietary quercetin information, miR
expression from lung tissue, and clinical data is warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Mean expression levels for significant miR groups comparing the highest vs. lowest tertile
of quercetin-rich food intake in former smokers with adenocarcinoma
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Table 2
MiRs that significantly (at P<0.05) differentiate highest (T3) versus lowest (T1) consumers of quercetin-rich
food intake, separately by histology
T1 mean ± SD T3 mean ± SD Fold Change* P-value**
Adenocarcinoma (n=97)
hsa-miR-502 0.085 ± 0.353 0.202 ± 0.350 1.124 0.017
hsa-mir-564 0.565 ± 0.258 0.449 ± 0.273 0.890 0.030
hsa-miR-124a 0.232 ± 0.447 0.072 ± 0.423 0.852 0.044
hsa-miR-125a 0.625 ± 0.723 1.034 ± 0.715 1.505 0.045
Squamous Cell Carcinoma (n=78)
hsa-miR-510 0.283 ± 0.361 0.147 ± 0.295 0.872 0.003
hsa-mir-605 2.118 ± 0.815 1.279 ± 0.765 0.432 0.004
hsa-miR-155 −5.113 ± 1.071 −4.777 ± 0.784 1.399 0.012
hsa-miR-373 −0.005 ± 0.420 −0.091 ± 0.330 0.917 0.014
hsa-miR-453 0.597 ± 0.324 0.491 ± 0.211 0.899 0.017
hsa-miR-502 0.318 ± 0.309 0.095 ± 0.223 0.801 0.017
hsa-miR-18b −2.621 ± 0.735 −2.227 ± 0.724 1.483 0.020
hsa-miR-183 1.160 ± 0.495 0.779 ± 0.470 0.683 0.022
hsa-mir-573 0.267 ± 0.355 0.126 ± 0.406 0.869 0.024
hsa-miR-524* 0.074 ± 0.259 −0.082 ± 0.341 0.855 0.036
hsa-mir-612 −0.171 ± 0.851 −0.104 ± 0.719 1.069 0.042
hsa-miR-363* −0.076 ± 0.778 0.124 ± 0.703 1.222 0.046
*
Fold change is the ratio (T3/T1) of geometric means (>1.0 indicates upregulation and < 1.0 downregulation)
**Coefficient P-value from ANOVA model adjusted for age, sex, BMI, smoking status, non-quercetin-rich fruits and vegetables, red/processed
meat, alcohol, and cigarette packyears
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